Investigation of Laboratory Findings, Hospitalization Day and Ex Rates of COVID-19 Patients with Comorbidity

Yıl 2022, Cilt: 6 Sayı: 2, 233 - 244, 31.05.2022

Recai Aci , Adem Keskin , Murat Arı

https://doi.org/10.46237/amusbfd.971668

Cited By: 2

Öz

Objective: The purpose of the present study was to investigate the laboratory findings in terms of comorbidity, taking into account the length of hospital stay and death rates of COVID-19 patients.
Method: Forty-four patients with COVID-19 hospitalized in intensive care unit and 71 patients hospitalized in the ward were included in this study. Whole blood parameters, C-Reactive Protein (CRP), Procalcitonin, Ferritin, Erythrocyte Sedimentation Rate (ESR), Troponin-I, Creatine, Prothrombin time (PT), Activated partial thromboplastin time (aPTT) International normalized ratio (INR) and D-Dimer results of the patients between hospitalization day and death rate correlation analysis was performed. In addition, the effects of these parameters on comorbid diseases were evaluated.
Results: PT, INR, CRP, Ferritin, Procalcitonin, ESR, D-Dimer, Troponin-I, White blood cell, Neutrophil, Monocyte Lymphocyte Ratio, Neutrophil Lymphocyte Ratio levels of the patients were positively correlated with hospitalization day and death rate, while Lymphocyte levels showed a negative correlation. It also showed a positive correlation with ex rate and Monocyte, Creatine and Platelet levels.
Conclusion: It was determined that patients with Chronic Obstructive Pulmonary Disease, Pneumonia comorbidities and Cardiovascular Disease had higher hospitalization days and intensive care unit admission rates than patients without comorbidity. In addition, patients with Diabetes, Cancer and Chronic Kidney Failure were found to have higher rates of intensive care admission compared to patients without comorbidity.

Anahtar Kelimeler

COVID-19, Comorbidity, Ex rate

Komorbiditesi Olan COVID-19 Hastalarının Laboratuvar Bulguları, Hastanede Yatış ve Ölüm Oranlarının İncelenmesi

Öz

Amaç: Bu çalışmada, COVID-19 hastalarının hastanede kalış süreleri ve ölüm oranları dikkate alınarak laboratuvar bulguları komorbidite yönünden incelenmesi amaçlandı.
Yöntem: Yoğun bakım ünitesinde yatan 44 COVID-19 hastası ve serviste yatan 71 hasta çalışmaya dahil edildi. Hastaların Tam kan parametreleri, C-Reaktif Protein (CRP), Prokalsitonin, Ferritin, Eritrosit Sedimantasyon Hızı (ESR), Troponin-I, Kreatin, Protrombin zamanı (PT), Aktive parsiyel tromboplastin zamanı (aPTT) Uluslararası normalleştirilmiş oran (INR) ve D-Dimer sonuçları ile hastanede yatış günü ve ölüm oranı arasında korelasyon analizi yapıldı. Ayrıca bu parametrelerin komorbidite hastalıklarının etkileri değerlendirildi.
Bulgular: Hastaların PT, INR, CRP, Ferritin, Prokalsitonin, ESR, D-Dimer, Troponin-I, Beyaz kan hücresi, Nötrofil, Monosit Lenfosit Oranı, Nötrofil Lenfosit Oranı düzeyleri, hastanede yatış günü ve ölüm oranı ile pozitif korelasyon gösterirken Lenfosit düzeyleri, negatif korelasyon göstermiştir. Ayrıca ölüm oranı ile Monosit, Kreatin ve Platelet düzeyleriyle de pozitif korelasyon göstermiştir.
Sonuç: Kardiyovasküler Hastalığı, Kronik Obstrüktif Akciğer Hastalığı ve Pnomöni komorbiditesi olan hastaların hastanede yatış günü ve yoğun bakıma yatma oranları komorbiditesi olmayan hastalara göre daha yüksek olduğu saptanmıştır. Ayrıca Diyabet, Kanser ve Kronik Böbrek yetmezliği olan hastaların yoğun bakıma yatma oranları komorbiditesi olmayan hastalara göre daha yüksek olduğu saptanmıştır.

Anahtar Kelimeler

COVID-19, Komorbidite, Ölüm oranı

Kaynakça

• 1. Chen, N., Zhou, M., Dong X, Qu, J., Gong, F., Han, Y., et al. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 395 (10223), 507-513.
• 2. Badawi, A., Ryoo, S. G. (2016). Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. International Journal of Infectious Diseases, 49, 129-133.
• 3. Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H. (2020). Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respiration Medicine, 8 (5), 475-481.
• 4. Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., et al. (2020). A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med, 382, 727-733.
• 5. Simonnet, A., Chetboun, M., Poissy, J., Raverdy, V., Nolulette, J., Duhamel, A et al. (2020). High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity, 28 (7), 1195-1199.
• 6. Yin, Y., Wunderink, R. G. (2018). MERS, SARS and other coronaviruses as causes of pneumonia. Respirology, 23 (2), 130-137.
• 7. Guo, Y. R., Cao, Q. D., Hong, Z. S., Tan Y. Y., Chen, S. D., Jin H. J. (2020). The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak—an update on the status. Military Medical Research, 7 (1), 1-10.
• 8. Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 395 (10229), 1054-1062.
• 9. Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., et al. (2020). Clinical and immunological features of severe and moderate coronavirus disease 2019. Journal of Clinical Investigation, 130 (5), 2620-2629.
• 10. Li B, Yang J, Zhao F. (2020). Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clinical Research in Cardiology, 109, 531–538.
• 11. Huang, I., Lim, M. A., Pranata, R. (2020). Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia - A systematic review, meta-analysis, and meta-regression. Diabetes Metabolic Syndrome, 14, 395–403.
• 12. Guan, W. J., Ni, Z. Y., Hu, Y., Liang, W. H., Ou, C. Q., He, J. X. (2020). Medical treatment expert group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine, 382, 1708-1720.
• 13. Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, X., Xu, S. (2020). Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA International Medicine, 180 (7), 934-943.
• 14. Qiu, H., Tong, Z., Ma, P., Hu, M., Peng, Z., Wu, W. (2020). Intensive care during the coronavirus epidemic. Intensive Care Medicine, 46, 576-578.
• 15. Liu, W., Tao, Z. W., Wang, L., Yuan, M. L, Liu, K., Zhou, L. (2020). Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chinese Medical Journal, 133 (9), 1032-1038.
• 16. Chan, J., Ng, C., Chan, Y., Mok, T., Lee, S., Chu, S. (2003). Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax, 58 (8), 686-689.
• 17. Zheng, Y. Y., Ma Y. T., Zhang, J. Y., Xie, X. (2020). COVID-19 and the cardiovascular system. Nature Reviews Cardiology, 17 (5), 259-260.
• 18. Tang, N., Li, D., Wang, X., Sun, Z. (2020). Abnormal coagulation parameters areassociated with poor prognosis in patients with novel coronavirus pneumonia. Journal of Thrombosis and Haemostasis, 18, 844- 847.
• 19. Sun, J., Zhu, A., Li, H., Zheng, K., Zhuang, Z., Chen, Z. (2020). Isolation of infectious SARS-CoV-2 from urine of a COVID-19 patient. Emerging Microbes & Infections, 9 (1), 991–993.
• 20. Chen, Y. T., Shao, S. C., Lai, E. C., Hung, M. J., Chen, Y. C. (2020). Mortality rate of acute kidney injury in SARS, MERS, and COVID-19 infection: a systematic review and meta-analysis. Critical Care, 24 (1), 439.
• 21. Guan, W., Ni, Z., Hu, Y., Liang, W., Ou, C., He, J., et al. (2020). Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine, 382 (18), 1708-1720.
• 22. Hu, L., Chen, S., Fu, Y., Gao, Z., Long, H., Wang, J. (2020). Risk factors associated with clinical outcomes in 323 COVID-19 hospitalized patients in Wuhan, China. Clinical Infectious Disease, 3, 539.
• 23. Zheng, R. S., Sun, K. X., Zhang, S. W, Zheng H. M., Zou, X. N., Chen, R., et al. (2019). Report of cancer epidemiology in China, 2015. Zhonghua Zhong Liu Za Zhi, 41, 19-28.
• 24. Liang, W., Guan, W., Chen, R., Wang, W., Li, J., Xu, K., et al. (2020). Cancer patients in SARS-CoV-2 infection: a nation wide analysis in China. Lancet Oncology, 21, 335-337.
• 25. Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J. (2020). Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 323 (11), 1061-1069.